FES-PET Enhances Treatment For Metastatic Breast Cancer, Study Indicates.

Aunt Minnie (8/7, Forrest) reports that according to a study published in the August issue of the Journal of Nuclear Medicine, “clinicians can better direct treatment for patients with metastatic breast cancer” by “identifying differences in estrogen receptor (ER) expression through PET imaging with the tracer F-18 fluoroestradiol (FES).” Senior author Dr. Geke Hospers, PhD, from the University of Groningen said in a statement, “We concluded that F-18 FES uptake in both tumor and normal tissue uptake is heterogeneous and influenced by the site of metastasis,” adding, “This heterogeneity of estrogen receptor expression is, therefore, really common, and it likely affects treatment outcome.”

Author: Nicole Hardy

Categories: NewsNumber of views: 117